Skip to main content

Table 4 Distribution of lipids profile in different ApoE isoforms and the response to statins

From: Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia

Lipid levels

E2 (n = 164)

E3 (n = 647)

E4 (n = 191)

P value

before

 TG

2.14 (1.30–3.00)

1.83 (1.24–2.48)

1.81 (1.24–2.68)

0.031

 TC

4.80 (4.31–5.44)

4.87 (4.22–5.68)

5.01 (4.27–5.69)

 HDL-C

1.06 (0.92–1.32)

1.09 (0.94–1.31)

1.11 (0.94–1.27)

 LDL-C

2.68 (2.29–3.28)

2.92 (2.40–3.59)

3.08 (2.43–3.73)

0.003

after

 TG

1.54 (1.03–2.14)

1.48 (1.08–1.91)

1.47 (1.05–2.13)

 TC

3.64 (3.12–4.37)

3.84 (3.25–4.51)

4.09 (3.33–4.95)

0.002

 HDL-C

1.11 (0.90–1.32)

1.08 (0.91–1.29)

1.08 (0.91–1.27)

 LDL-C

1.89 (1.50–2.35)

2.08 (1.68–2.68)

2.25 (1.76–2.87)

< 0.001

reduction %

 TG

25.20 (5.30–41.57)

21.03(−0.68–35.84)

16.02(− 4.17–33.33)

0.021

 TC

23.56 (10.73–31.24)

20.49 (10.70–30.47)

17.92 (5.20–28.92)

0.012

 HDL-C

−4.65(−17.56–10.58)

0.85(− 13.51–11.94)

0(−12.94–11.38)

 LDL-C

29.41 (13.47–43.14)

27.25 (13.53–38.70)

23.05 (12.47–38.46)

0.042

  1. Values are expressed as M (p25, p75); TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; p-values from K-W test, “-” means P > 0.05. E2: e2/e2 and e2/e3, E3: e3/e3 and e2/e4, E4: e3/e4 and e4/e4; “before”: before statin therapy; “after”: after statin therapy